published 20-years follow-up scientific data confirm that there
is no difference in survival after breast conservation therapy
or total mastectomy in women with stage I or II breast cancer.
However, breast conservation treatment is associated with an
increased risk of both positive
margins and local
recurrence. Current estimates suggest that 10
to 20% of women after breast-conserving treatment is at high-risk
of local failures. This is a characteristic example of limitations
and lack of generalizability of randomized controlled trials,
which are the gold standard for treatment decision-making.
the women at high-risk of local failure be identified and how
can we minimize the risk of local